Abstract
This study has sought to evaluate patient exposures during the course of particular diagnostic positron emission tomography and computed tomography (PET/CT) techniques. A total of 73 patients were examined using two types of radiopharmaceutical: F-18-fluorocholine (FCH, 48 patients) and Ga-68-prostate-specific membrane antigen (PSMA, 25 patients). The mean and range of administered activity (AA) in MBq, and effective dose (mSv) for FCH were 314.4 +/- 61.6 (462.5-216.8) and 5.9 +/- 1.2 (8.8-4.11), respectively. Quoted in the same set of units, the mean and range of AA and effective dose for Ga-68-PSMA were 179.3 +/- 92.3 (603.1-115.1) and 17.9 +/- 9.2 (60.3-11.5). Patient effective doses from F-18-FCH being a factor of two greater than the dose resulting from Ga-68-PSMA PET/CT procedures. CT accounts for some 84 and 23% for F-18-FCH and Ga-68-PSMA procedures, accordingly CT acquisition parameter optimization is recommended. Patient doses have been found to be slightly greater than previous studies.